Positive overall survival data with Roche's recently approved Zelboraf
This article was originally published in Scrip
Executive Summary
Just days after receiving European approval, new data have been published on Roche's melanoma medication Zelboraf (vemurafenib), showing a median overall survival of approximately 16 months.